Targeting the FLT3 kinase, midostaurin has been approved for the treatment of newly diagnosed FLT3 mutant AML; gilteritinib has been approved recently for relapsed/refractory (R/R) AML10,11. This evidence concerns the gene FLT3 and acute myeloid leukemia.